Board of Directors


Chairman, Dr. Peter Hirth, M.Sc., PhD

Dr. Hirth has an exceptional history of value creation in the field of oncology and has led the development of a range of new therapies in the field, co-founding or leading companies such as SUGEN, Plexxikon and Daiichi Sankyo. He serves or has served on the board or advisory board of several companies, including Iconic Therapeutics, SutroVax, Afferent Pharma (acquired by Merck in 2016), Alios BioPharma, Inc. (acquired in 2014) and Trovagene, Inc. Dr. Hirth received his M.Sc. and his Ph.D. degrees in molecular genetics from Heidelberg University, Germany, and completed his post-doctoral work at the University of California, San Diego. management.

Founder, CSO and member of BoD, Professor Mads Hald Andersen

Professor and Director of CCIT (Center for Cancer Immune Therapy at Herlev University Hospital, Mads Hald Andersen has received several honors for his scientific work and is the author of more than 130 papers. Mads Hald Andersen has founded and co-founded several spin-out companies with a successful sale of Survac in 2003.

Member of BoD, Stephan Christgau, PhD

Stephan Christgau, Ph.D., joined Novo A/S in September 2007 as Investment Director of Novo Seeds. Prior to joining Novo Seeds, he was Executive Vice President and Chief Operating Officer at Osteologix where he played a leading role in the development of the company, taking the lead candidate drug through all stages from lead identification to Phase II testing for osteoporosis treatment. Previously, Stephan Christgau worked in the metabolic bone disease and arthritis areas in Nordic Bioscience and Osteometer Biotech and as a protein chemist in Novo Nordisk A/S. Stephan Christgau is the author of more than 60 scientific publications and inventor on more than 30 patent families. 

Member of BoD, Christian Elling, PhD

Christian Elling is a partner at Lundbeckfonden where he leads its early stage investment unit, Lundbeckfonden Emerge. He joined Lundbeckfonden in 2012. He is CEO of Insusense Therapeutics, a Lundbeckfonden portfolio company, and former board member of Epitherapeutics (sold in 2015) and Inagen. Prior to joining Lundbeckfonden, Christian Elling was VP and later CEO of 7TM Pharma, which he also co-founded. Christian Elling received his early training in Biochemistry and received his Ph.D. from the University of Copenhagen, Denmark. He serves on the steering committee for Biopeople for The Danish Association of Biotechnology Industries and is a member of The Danish Academy of Technical Sciences.

Member of BoD, Claus Andersson, M.Sc., PhD

Claus Andersson is a partner in Sunstone Life Science Ventures and has been with the team since it was established. Claus focuses on medical technology, diagnostics and therapeutics investments and is actively involved in maintaining a strong network to universities and research centers. Claus Andersson has extensive experience in strategy execution and technology development from various parts of the Life Science ecosystem: both as an entrepreneur, venture capitalist, scientist, and corporate manager. Claus Andersson holds a Master’s degree in Civil Chemical Engineering from the Technical University of Denmark (DTU) and a Ph.D. in Mathematical Statistics from the University of Copenhagen and the Humboldt University in Berlin.

Member of Board, Kathleen Sereda Glaub, MBA

Ms. Glaub brings more than 30 years of experience in executive-level corporate development, financing and company-building for leading life science and technology innovation-based companies. Most recently, as Chief Executive Officer of Afferent Pharmaceuticals from 2014-2016, Ms. Glaub led the company’s development of it lead molecule, AF-219/MK-7264, through a full complement of mid-stage clinical trials to Phase 3 readiness as a novel treatment for chronic cough, and ultimately, the sale of the company to Merck in 2016 for USD 1.25 billion, including USD 500 million upfront. She also raised USD 80 million additional private funding, including a crossover round. She had joined the Afferent Board in 2013. Prior to Afferent, Ms. Glaub co-led Plexxikon Inc. as President for 12 years, until May 2013. In this role, she led the business and financing strategy for the company, including negotiating six partnerships generating over several hundred million in non-equity funding, and led the company’s buyout by Daiichi Sankyo for nearly USD 1 billion cash in 2011.  Prior experience also included positions as SVP & CFO of Cell Genesys, Treasurer of Genentech, and various finance and treasury roles with Intel Corporation. Ms. Glaub received her MBA from Northwestern University, and her BA from the University of California, Berkeley.